Over 180 Companies From Different Regions Across The Globe Presently Claim To Provide Services For The Development Of Companion Diagnostic Tests, Claims Roots Analysis


Over 180 companies from different regions across the globe presently claim to provide services for the development of companion diagnostic tests, claims Roots Analysis

It is estimated that around 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise. On the other hand, there are numerous contract service providers, offering vast portfolios of services for diagnostic test / assay development. Such companies are known to possess extensive technical knowledge, and experience in working with cutting-edge analytical tools and technologies, such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR).

To  order this 320+ page report, which features 120+ figures and 115+ tables, please visit this link

The USD 800+ million (by 2030) financial opportunity within the companion diagnostics development services market has been analysed across the following segments:

  • Type of Service Offered
  • Feasibility Studies
  • Assay Development
  • Analytical Validation
  • Clinical Validation
  • Type of Assay Technique Used
  • in situ hybridization / Immunohistochemistry
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Others
  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific

The report features inputs from eminent industry stakeholders, according to whom the development of companion diagnostics is largely outsourced, owing to the exorbitant costs associated with the setting-up of in-house expertise / capabilities. The report includes detailed transcripts of discussions held with the following experts:

  • Anton Iliuk (President and Chief Technology Officer, Tymora Analytica)
  • Paul Kortschak (Senior Vice President, Novodiax)
  • Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
  • Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

Table of Contents

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Market Landscape

  4. Company Profiles
  5. Partnerships and Collaborations

  6. Likely Partner Analysis

  7. Company Competitiveness Analysis

  8. Stakeholder Needs Analysis

  9. Value Chain Analysis
  1. Clinical Research on Cancer Biomarkers: Big Pharma Perspective
  1. Market Forecast And Opportunity Analysis
  2. Executive Insights
  3. Appendix 1: Tabulated Data
  4. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415



Keywords: biotech,reseach,analysis,pharma


Other related blogs

The “Prefilled Syringe Fill / Finish Service Providers, 2020-2030” report features an extensive study of the current market

By : Roots Analysis

Key Inclusions A detailed review of the overall landscape of companies offering contract fill / f..

The prefilled syringe fill / finish services market is projected to grow at an annualized rate of over 10%, till 2030

By : Roots Analysis

Roots Analysis has done a detailed study on Prefilled Syringe Fill / Finish Services Market, 2020-20..

The prefilled syringe fill / finish services market is estimated to is estimated to reach close to USD 3 Billion by 2030

By : Roots Analysis

The numerous benefits offered by prefilled syringes, coupled to the growing self-medication trend, h..